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Abstract
Background: Among the tropical parasitic diseases, those caused by protozoans are considered a challenge to
public health, being represented by leishmaniasis and Chagas disease. In view of the low effectiveness and toxicity
of the current therapy, animal venoms such as amphibian secretions have been used as a promising source of new
drug prototypes. The present work aimed to achieve bioguided fractionation of metabolites present in a cutaneous
secretion of the caecilian Siphonops annulatus (Amphibia: Gymnophiona: Siphonopidae) with antileishmanial and
antitrypanosomal activity.
Methods: Through liquid-liquid partition and chromatographic techniques, the secretion was fractionated using
bioguided assays. The 50% inhibitory concentration (IC50) of the main fraction (SaFr1) was studied against Leishmania
(L.) infantum promastigotes and intracellular amastigotes, trypomastigotes of Trypanosoma cruzi and mammalian cells;
viability was detected by the colorimetric MTT assay. By using a spectrofluorimetric assay with the probe SYTOX® Green
and transmission electron microscopy (TEM), we also investigated the potential damage caused by SaFr1 in the plasma
membrane and mitochondria of Leishmania.
Results: The bioguided assay enabled isolation of a highly purified fraction (SaFr1) with an IC50 of 0.065 μg/mL
against promastigotes and 2.75 μg/mL against trypomastigotes. Due to its high toxicity to peritoneal macrophages,
SaFr1 showed no selectivity towards the intracellular forms of Leishmania. Ultrastructural studies with Leishmania
demonstrated severe mitochondrial damage and the formation of large cytoplasmic vacuoles, leading to the parasite’s
death within a few hours. Nevertheless, it caused no alteration in the plasma membrane permeability as detected by
the fluorescent probe and TEM.
Conclusions: The present study demonstrated for the first time the antiparasitic activity of the skin secretion of the
caecilian S. annulatus against Leishmania and T. cruzi, confirming that skin secretions of these amphibians, similarly to
those of anurans and salamanders, are also potential tools for the development of new drug candidates against
neglected diseases.
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Background
Among the natural toxins used as important tools in the
development of new drugs, amphibian secretions repre-
sent a rich source of metabolites, providing potential
candidates for drug design studies. Leishmaniasis is a
complex of diseases caused by protozoan parasites of the
genus Leishmania. Included among the tropical neglected
diseases, it is endemic in 98 countries, with a global inci-
dence estimated at approximately 1.3 million cases each
year; Brazil is included among the ten countries with the
highest number of estimated cases [1]. The therapy is
based on the use of a few drugs such as pentavalent anti-
monials and amphotericin B, with medium to severe toxic
side effects and long-term administration [2].
American trypanosomiasis or Chagas disease has been
considered among the most neglected afflictions in
several underdeveloped and developing countries, and
affects about 28 million people in Latin America [3]. It is
caused by the flagellate protozoan parasite Trypanosoma
cruzi and is transmitted to humans by triatomine insects
primarily during insect feeding, or by blood transfusion
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and congenital transmission [4]. The only drug available
in Brazil within the highly limited therapeutic arsenal is
benznidazole, which presents limited efficacy in the
chronic phase and high toxicity [5]. Thus, there is an
essential need for the discovery of new drug entities,
using animal toxins as a source [6,7].
Amphibian secretions represent a rich source of bio-
active peptides, including metabolites such as steroids,
alkaloids, biogenic amines and proteins [8-10]. A variety of
antimicrobial peptides (AMPs) present in amphibian skin
secretion has been well characterized, showing activity
against bacteria, such protozoan parasites as Trypanosoma
cruzi and Leishmania, fungi and viruses [8,11-15].
In the present work, by using bioguided fractionation,
we investigated the antiprotozoal activity of metabolites
isolated from the cutaneous secretion of the Brazilian
caecilian Siphonops annulatus (Amphibia: Gymnophiona:
Siphonopidae) using liquid-liquid partition and reversed-
phase ultra-performance liquid chromatography, coupled
to a photodiode array detector (RP-UPLC-PDA). We also
investigated the ultrastructural damage in Leishmania, as
well as the potential interference of the active fraction in
the plasma membrane permeability of the parasite, and its
mammalian cytotoxicity.
Methods
Materials
Sodium dodecyl sulfate (SDS), 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT; thiazol blue),
M-199 and RPMI-PR-1640 medium were purchased from
Sigma (St. Louis, USA). Pentavalent antimony (Glucan-
time®, Aventis-Pharma, Brazil) miltefosine and benznida-
zole were used as standard drugs. All solvents used were
grade HPLC of J.T. Baker. The other analytical reagents
were purchased from Sigma (St. Louis, USA).
Amphibian secretion
Specimens of Siphonops annulatus were collected at Ilhéus
(Bahia state, Brazil). The skin secretion of S. annulatus
(800 mg) was obtained by mild mechanical stimulus of ani-
mals submerged in deionized water at Butantan Institute.
The secretion was then lyophilized and stored at −20°C.
Bioguided amphibian-secretion fractionation
The pre-fractionation of crude venom was conducted
using liquid-liquid partition with solvents of increasing
polarity (n-hexane, ethyl acetate and butane). The hex-
ane fraction (SaFrHex) and ethyl acetate fraction of
S. annulatus (SaFrAcEt) were analyzed by reversed-phase
ultra-performance liquid chromatography (RP-UPLC) using
a binary UPLC system (20A Prominence, Shimadzu Co.,
Japan), in a C18 column (ACE C18, 5 μm, 100 Å, 250 mm
× 4.6 mm). These fractions were diluted in methanol and
applied in the column (10 μL). The column was eluted at a
constant flow rate of 1 mL.min−1 in a gradient of methanol
(solvent B) and water (solvent A). Elution of the fractions
were monitored in a range of 200–800 nm, using a photo-
diode array detector. The fractions with the same retention
time were pooled. The biological activity was detected using
in vitro incubation of fractions of L. (L.) infantum promasti-
gotes and Trypanosoma cruzi trypomastigotes for 24 hours.
Bioassay procedures
BALB/c mice and golden hamsters were supplied by the
Animal Breeding Facility at the Adolfo Lutz Institute of
São Paulo. They were maintained in sterilized cages under
a controlled environment, receiving water and food
ad libitum. Animal procedures were performed with the
approval of the Research Ethics Commission, in agree-
ment with the Guide for the Care and Use of Laboratory
Animals from the National Academy of Sciences (http://
www.nas.edu).
Parasite maintenance
L. (L.) infantum (MHOM/BR/1972/LD) was maintained
in Golden hamsters, up to approximately 60 to 70 days
post-infection [16]. Promastigotes were maintained in
M-199 medium supplemented with 10% calf serum and
0.25% hemin at 24°C. Trypomastigotes of Trypanosoma
cruzi were maintained in LLC-MK2 (ATCC CCL 7) cells
using Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 2% calf serum at 37°C in a
5% CO2 incubator [17].
Mammalian cells
Peritoneal macrophages were collected from the periton-
eal cavity of female BALB/c mice by washing with
RPMI-1640 without phenol red, supplemented with 10%
fetal calf serum. Rhesus monkey kidney cells (LLC-MK2)
were maintained in RPMI-1640 medium without phenol
red and supplemented with 10% fetal calf serum at 37°C
in a 5% CO2 incubator [17].
Determination of the 50% inhibitory concentration (IC50)
Antileishmanial activity
Promastigotes The antileishmanial activity was deter-
mined in L. (L.) infantum promastigotes, which were
counted in a Neubauer hemocytometer and seeded at
1 × 106 cells per well in 96-well microplates using milte-
fosine as the standard drug. The SaFrHex and SaFrAcEt
were tested at 300 μg/mL (based on dry weight). The
active fraction (SaFr1) was tested for 24 hours at 24°C,
in a concentration range between 150 μg/mL and
0.02 μg/mL (based in dry weight), using a serial dilution
(base 2). The parasite viability was determined using the
MTT assay at 570 nm [18]. Briefly, 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) was dis-
solved in phosphate-buffered saline (PBS) at 5 mg/mL and
Pinto et al. Journal of Venomous Animals and Toxins including Tropical Diseases 2014, 20:50 Page 2 of 8
http://www.jvat.org/content/20/1/50
incubated with cells (20 μL/well) for four hours under the
same conditions. The extraction of the mitochondrial
formazan was done with 80 μL of 10% SDS, followed by
24-hour incubation at 24°C. The optical density was read
at 570 nm (Multiskan) using control wells with Leish-
mania and without drugs (100% viability), with 0.5%
methanol, and without parasites (blank wells).
Amastigotes Briefly, peritoneal macrophages were
seeded at 1 × 105 cells/well in 16-well slide chambers
(NUNC®) (Thermo Scientific™, USA), infected with the
previously isolated (hamster spleen) L. (L.) infantum
amastigotes in a 1:10 ratio (macrophage/amastigote) and
treated with drugs for 120 hours at 37°C in an incubator
humidified with 5% CO2. At the end of the assay, the
macrophages were fixed with methanol, stained with
Giemsa and observed using light microscopy. The para-
site burden was verified using the number of infected
macrophages out of 400 cells [19] and Glucantime® was
used as the standard drug. The data obtained represent
the mean of two independent assays, and each assay was
performed in duplicate.
Antitrypanosomal activity
Free trypomastigotes obtained from LLC-MK2 cultures
were counted in a Neubauer hemocytometer and seeded
at 1 × 106 cells per well in 96-well microplates. The active
fraction (SaFr1) was incubated at 150 μg/mL for 24 hours
at 37°C in a 5% CO2 incubator. Benznidazole was used as
the standard drug. Parasite viability was determined using
the MTT assay, as previously described [20].
Cytotoxicity against mammalian cells
Macrophages were obtained as previously described and
seeded at 4 × 105 cells per well in 96-well microplates.
The cells were incubated with the active fraction (SaFr1)
at 100 μg/mL for 48 hours at 37°C in a 5% CO2 incuba-
tor. The viability of macrophages was determined using
the MTT assay as previously described [18]. Miltefosine,
Glucantime® and benznidazole were used as standard
drugs [8].
Transmission electron microscopy analysis
L. (L.) infantum promastigotes were incubated with
S. annulatus active fraction (SaFr1) and the ultrastruc-
tural changes were observed for different periods (1, 2, 4,
16 hours). Subsequently, promastigotes were fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate/0.2 M sucrose
buffer, pH 7.2. One percent osmium tetroxide post-
fixation was followed by 1% uranyl acetate treatment. The
samples were dehydrated through an acetone series and
embedded in Epon. Ultrathin sections were stained with
uranyl acetate and lead citrate. The material was examined
in a JEOL 1011 transmission electron microscope (USA).
Evaluation of the Leishmania plasma membrane
permeability
Late-growth-phase (non-stationary) promastigotes were
washed in PBS, seeded at 2 × 106/well and incubated
with 1 μM SYTOX® Green (Molecular Probes®, Invitro-
gen, USA) for 15 minutes at 24°C, in the dark [21]. The
active fraction (SaFr1) was added and the fluorescence
was measured every 30 minutes (up to 120 minutes).
The control with maximum permeabilization was ob-
tained with 0.1% Triton X-100. The fluorescence inten-
sity was determined using a fluorimetric microplate
reader (FilterMax™ F5 Multi-Mode Microplate Reader,
Molecular Devices, USA) with excitation and emission
wavelengths of 485 and 520 nm, respectively.
Statistical analysis
The obtained data represent the mean and standard
deviation of duplicate samples from two independent
assays. The IC50 values were calculated using sigmoid
dose–response curves generated by the software Graph-
Pad Prism version 5.0 for Windows (GraphPad Software,
USA), and the 95% confidence intervals are included in
parentheses.
Results
S. annulatus secretion fractionation
The HPLC-bioguided fractionation of the S. annulatus
secretion showed two active fractions (n-hexane and
ethyl acetate). Analytical chromatography revealed the
presence of a major peak in both fractions. After com-
paring their retention times and the similarity of the
chromatographic profile of the hexane and ethyl acetate
fractions, the peaks with the same retention times were
pooled (named SaFr1), resulting in a high purity fraction
(98%) as determined by RP-UPLC-PDA (Figure 1). After
several injections, the total amount of SaFr1 isolated was
1.3 mg, which comprised only 0.16% of the total mass.
Antiparasitic activity and mammalian toxicity
The hexane and ethyl acetate fractions eliminated 100%
of promastigotes at the tested concentrations. Promasti-
gotes were incubated with SaFr1 for 24 hours at differ-
ent concentrations and the cell viability was determined
by the MTT method. The SaFr1 was active at the highest
tested concentration, with an IC50 value of 0.065 μg/mL
(95% CI 0.0519 to 0.0816 μg/mL). Miltefosine was used as
a standard drug and showed an IC50 value of 27.26 μg/mL
(95% CI 25.63 to 28.97 μg/mL) (Table 1). Subsequently,
the SaFr1 was tested against the intracellular Leishmania
amastigotes, but it showed no activity.
Trypomastigotes of T. cruzi were incubated with SaFr1
for 24 hours at different concentrations and the cell via-
bility was also determined by MTT assay. The SaFr1
showed an IC50 value of 2.75 μg/mL (95% CI 2.235 to
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3.396 μg/mL) (Table 1). Benznidazole was used as the
standard drug and showed an IC50 value of 114.68 μg/mL
(95% CI 105.69 to 124.49 μg/mL).
In order to evaluate the cytotoxicity to mammalian cells,
peritoneal macrophages were incubated for 48 hours with
SaFr1 and the cell viability was determined by the MTT
method. The SaFr1 showed an IC50 value of 0.278 μg/mL
(95% CI 0.231 to 0.336 μg/mL) (Table 1).
Ultrastructural studies
The ultrastructural studies of L. (L.) infantum promasti-
gotes demonstrated an intense time-dependent cellular
damage, namely mitochondrial swelling within the initial
incubation times (1–4 hours), and loss of cytoplasmatic
organelles at 16 hours, leading to parasite death (Figure 2).
At one hour of incubation (Figure 2B), a pronounced
swelling of mitochondria and an increasing formation of
large cytoplasmic vacuoles were observed; after two hours
of incubation (Figure 2C), the morphology of the parasite
became visibly altered. At four hours of incubation
(Figures 2D and E), there was a continuous mitochondrial
damage and formation of vacuoles containing cellular
membranes. Finally, after 16 hours of incubation (Figure 2F),
all cytoplasmic organelles were lost, including nucleoli,
with a predominant round shape, confirming the death
of the parasite. Although the SaFr1 caused intense
cellular damage, no pore-forming activity was observ-
able in the plasma membrane, which showed a pre-
served microtubule architecture.
Evaluation of the plasma membrane permeability of L. (L.)
infantum promastigotes
The SaFr1 was incubated with promastigotes and the
plasma membrane permeability was evaluated with vital
dye SYTOX® Green. The SaFr1 showed no interference
with the plasma membrane after 120 minutes of incuba-
tion, which signifies no increase in the fluorescence
intensity when compared to the untreated control group.
Triton-X 100 was used as a positive control and resulted
in an elevated fluorescence intensity (Figure 3).
Figure 1 Chromatographic profile of hexane and ethyl acetate unified fractions obtained by RP-UPLC-PDA in a C18 column (ACE C18,
5 μm, 100 Å, 250 mm×4.6 mm) at a constant flow rate of 1 mL/min−1 using water as solvent A and MeOH as solvent B. The chromatogram
was obtained at wavelengths of 214 and 254 nm.
Table 1 Antiparasitic activity and cytotoxicity of SaFr1, the viability was determined by the colorimetric assay of MTT
at 570 nm
Compounds IC50 mμg/mL) (95% CI)
L. (L.) infantum promastigotes L. (L.) infantum amastigotes T. cruzi trypomastigotes Macrophages cytotoxicity
SaFr1 0.065 (0.051-0.081) NA 2.755 (2.235-3.396) 0.278 (0.231-0.336)
Miltefosine 27.26 (25.63-28.97) 17.80 (11.57-24.57) – 122.0 (94.78-157.00)
Glucantime NA 25.0 (24.40-25.63) – >200
Benznidazole – – 114.68 (105.69-124.49) 469.93 (414.98-532.18)
IC50: 50% inhibitory concentration; 95% CI: 95% confidence interval; NA: not active.
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Discussion
Amphibian secretions have been used as an important
tool in the search for new compounds [11]. Previous
studies demonstrated that two bufadienolides, specifically
telocinobufagin and hellebrigenin isolated from the toad
Rhinella jimi, showed anti-Leishmania and anti-T. cruzi
activity [9]. In the present study, using bioguided fraction-
ation of the caecilian S. annulatus secretion, we isolated
Figure 2 Evaluation of ultrastructural damage by transmission electron microscopy (TEM). Promastigotes of L. (L.) infantum were incubated
with SaFr1 at different times: (A) control (untreated); (B) one-hour incubation; (C) two-hour incubation; (D) and (E) four-hour incubation and
(F) 16-hour incubation. m: mitochondrial damage; v: vacuole; pm: plasma membrane integrity. Bar represents (A) 0.5 μm; (B) 1 μm; (C) 0.1 μm;
(D) 0.5 μm; (E) 100 nm; (F) 100 nm.
Pinto et al. Journal of Venomous Animals and Toxins including Tropical Diseases 2014, 20:50 Page 5 of 8
http://www.jvat.org/content/20/1/50
an active antiprotozoal fraction and studied its potential
against Leishmania and T. cruzi parasites. By using a
simple technique, namely liquid-liquid partition, an
initial separation of the organic components was estab-
lished, allowing the concentration of active compounds
into specific fractions [22]. After testing the fractions at
300 μg/mL against parasites, the hexane and ethyl
acetate fractions demonstrated activity by eliminating
100% of parasites after 24 hour of incubation. These
data demonstrated that the active compounds were
concentrated in the nonpolar fractions (n-hexane and
ethyl acetate), suggesting a hydrophobic nature of the
active compounds.
Subsequently, the active fractions from the liquid-
liquid partition were separated by the RP-UPLC system,
resulting in one major peak, which showed antiparasitic
activity at 150 μg/mL and a similar profile in both the
peak shape and retention time. Despite the high initial
amount of crude secretion, the pooled active fraction
yielded only 0.16% of the total mass, limiting further
characterization studies in nuclear magnetic resonance
(1H and 13C NMR) and mass spectrometry.
Based on the IC50 determination against L. (L.) infantum,
the isolated fraction (SaFr1) was clearly more effective than
the standard drug miltefosine, thus demonstrating a prom-
ising antileishmanial activity. To the best of our knowledge,
the uncommon IC50 value found for this fraction could be
included among the smallest values of natural products
with antileishmanial properties against L. (L.) infantum
promastigotes reported in the literature. Although
SaFr1 was promising against the extracellular promasti-
gotes, SaFr1 presented a lack of activity towards the
intracellular amastigotes, a finding partially attributable to
the lack of specific receptors in host cells, which might
have contributed to blocking the penetration of SaFr1 into
the intracellular macrophages [23]. Two steroids, namely
telocinobufagin and hellebrigenin, isolated from the secre-
tion of the toad Rhinella jimi, also demonstrated activity
against Leishmania and T. cruzi, whereas similarly to our
data, these secondary metabolites showed limited activity
against the intracellular amastigotes [9].
Amphibian peptides have also demonstrated signi-
ficant antiparasitic activity. Leite et al. [11] isolated
six active peptides from P. hypocondrialis secretion
(PS-1, −2, −3, −4, −5, and −6), showing activity against
gram-negative and gram-positive bacteria. Only PS-4 and
PS-5 demonstrated activity against T. cruzi trypomasti-
gotes, with IC50 values of 5.1 and 4.9 μM, respectively.
Brand et al. [12] also isolated six peptides (DShypo 1, 2, 3,
4, 6, and 7) with activity against S. aureus, E. coli and
L. (L.) amazonensis promastigotes. Nevertheless derma-
septins 1 and 4 and phylloseptins 7 and 8, isolated from
P. nordestina, demonstrated activity against T. cruzi para-
sites while only phylloseptin 7 presented activity against
L. (L.) infantum [8]. Despite demonstrating antiparasitic
effectiveness, SaFr1 presented high cytotoxicity in vitro
and confirmed the lack of selectivity against intracellular
amastigotes of Leishmania infantum. In our assays, T.
cruzi trypomastigotes were also affected by SaFr1, but
to a lesser extent than Leishmania; however, SaFr1 was
approximately 41 times more effective than the stand-
ard drug benznidazole.
Our ultrastructural studies demonstrated that SaFr1
caused intense damage to Leishmania promastigotes in
Figure 3 Evaluation of the plasma membrane permeability of L. (L.) infantum incubated with SaFr1 by SYTOX Green®. The fluorescence
intensity was determined using a fluorimetric microplate reader with excitation and emission wavelengths of 485 and 520 nm, respectively. Triton
X-100 was used as the positive control of the assay.
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an incubation period of less than 60 minutes, suggesting
a time-dependent autophagic process, with large vacu-
oles and mitochondrial swelling. Although a lethal effect
was evident after 16 hours of incubation, with losses of
all cytoplasmatic organelles, the SaFr1 induced no dam-
age to plasma membrane of Leishmania, as confirmed
by the organization of microtubules and membrane. This
observation was also corroborated by our fluorimetric
assay with the vital dye Sytox® green, suggesting a meta-
bolic interference in parasites rather than a pore-
forming activity. Conversely, the antimicrobial peptide,
phylloseptin 7, also demonstrated a potential antileish-
manial effect, but affected Leishmania promastigotes
through the permeabilization of the plasma membrane,
leading to the parasite’s death [8].
Conclusion
Amphibian secretions represent a rich source of peptides
and secondary metabolites with a wide spectrum of
activities as previously reported by Toledo and Jared
[10]. To the best of our knowledge, this is the first de-
scription of the antiparasitic activity found in a caecilian
(S. annulatus) amphibian secretion, which was detected
in a highly active fraction. If investigated in more detail
in further studies, these data could be exploited as a tool in
the search for novel biochemical targets against Leishmania
or T. cruzi.
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